Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for lung cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Impact of inhaled corticosteroids on the incidence of lungcancer in obstructive airway diseases: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration
Herbal medicine on cancer-related fatigue of lungcancer survivors: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites
Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed non-small cell lungcancer: a systematic review and meta-analysis of randomized clinical trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility
Lorlatinib (Lorbrena) - To treat patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lungcancer Drug Approval Package: LORBRENA (lorlatinib) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: LORBRENA (lorlatinib) Company: Pfizer, Inc. Application Number: 210868 Approval Date: 11/02/2018 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter
Patient Navigation Models for LungCancer Rapid Evidence Product Patient Navigation Models for LungCancer eRapid Evidence Product Patient Navigation Models for LungCancer Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. 290-2017-00003-C Prepared by: Scientific Resource Center Portland, OR Investigators: Jennifer Gilbert, M.D., M.P.H. Stephanie Veazie, M.P.H. Kevin Joines, B.S (...) , other quality enhancement tools, or reimbursement or coverage policies, may not be stated or implied. Persons using assistive technology may not be able to fully access information in this report. For assistance contact email@example.com. Suggested citation: Gilbert J, Veazie S, Joines K, Winchell K, Relevo R, Paynter R, Guise J-M. Patient Navigation Models for LungCancer. Rapid Evidence Product. (Prepared by Scientific Resource Center under Contract No. 290-2017-00003-C.) AHRQ Publication No. 18(19
Delivering best practice lungcancer care - a guide for health professionals This guide provides an overview of the LungCancer Framework, which can be accessed at: canceraustralia.gov.au/publications-and-resources/cancer-australia-publications/lung-cancer-framework A summary for health professionals Delivering best practice lungcancer care Cancer Australia’s LungCancer Framework: Principles for Best Practice LungCancer Care in Australia (the LungCancer Framework) is a national resource (...) for health professionals and service providers involved in the care and treatment of people affected by lungcancer. canceraustralia.gov.au The LungCancer Framework aims to improve the outcomes and experiences of people affected by lungcancer in Australia by supporting the uptake of five key principles in lungcancer care. Principles for best practice lungcancer care Cancer Australia’s Principles for best practice management of lungcancer in Australia have been informed by evidence from national
30-day mortality after the start of systemic anticancer therapy for lungcancer: is it really a useful performance indicator? Systemic treatment is the standard treatment for unresectable stage III and IV lungcancer. Nevertheless, a 5-10% death rate has been described within 30 days after the last systemic treatment, suggesting that these patient did not benefit. We analysed the 30-day mortality after start of systemic therapy. Data were retrieved from the Netherlands National Cancer Registry (...) . From 2010 to 2015, 26 277 patients were included. 56% were men. The median age was 65 years and 31% of patients were aged ≥70 years. 27% involved small cell lungcancer and 73% nonsmall cell lungcancer. Overall mortality within 30 days after the start of systemic treatment was 6.2%. Multivariable analysis established the prognostic influence of age, histology, number of metastatic sites and type of systemic treatment. Chemotherapy was administered in 77 hospitals, treating each 15-161 lungcancer
Screening for LungCancer: CHEST Guideline and Expert Panel Report Screening for LungCancer CHEST Guideline and Expert Panel Report Peter J. Mazzone, MD, MPH, FCCP; Gerard A. Silvestri, MD, FCCP; Sheena Patel, MPH; Jeffrey P. Kanne, MD, FCCP; Linda S. Kinsinger, MD; Renda Soylemez Wiener, MD, MPH; Guy Soo Hoo, MD, FCCP; and Frank C. Detterbeck, MD, FCCP BACKGROUND: Low-dose chest CTscreening for lungcancer has becomeastandard ofcare in the United States in the past few years, in large part (...) addressed resulting in six graded recommendations and nine ungraded consensus based statements. CONCLUSIONS: Evidence suggests that low-dose CT screening for lungcancer results in a favorable but tenuous balance of bene?t and harms. The selection of screen-eligible patients, thequalityofimagingandimageinterpretation,themanagementofscreen-detected?ndings, and the effectiveness of smoking cessation interventions can affect this balance. Additional research is needed to optimize the approach to low-dose
Bevacizumab (Mvasi) - Metastatic Colorectal Cancer (mCRC) or Locally Advanced, Metastatic or Recurrent Non-small Cell LungCancer (NSCLC) Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product
Metastatic Non-Small-Cell LungCancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up CLINICAL PRACTICE GUIDELINES Metastatic non-small cell lungcancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up † D. Planchard 1 , S. Popat 2 , K. Kerr 3 , S. Novello 4 , E. F. Smit 5 , C. Faivre-Finn 6 , T. S. Mok 7 , M. Reck 8 , P. E. Van Schil 9 , M. D. Hellmann 10 & S. Peters 11 , on behalf of the ESMO Guidelines Committee * 1 Department of Medical (...) : firstname.lastname@example.org † Approved by the ESMO Guidelines Committee: February 2002, last update September 2018. This publication supersedes the previously published version—Ann Oncol 2016; 27 (Suppl 5): v1–v27. Incidenceandepidemiology Primary lungcancer remains the most common malignancy after non-melanocytic skin cancer, and deaths from lungcancer ex- ceed those from any other malignancy worldwide . In 2012, lungcancer was the most frequently diagnosed cancer in males with an estimated 1.2 million
Atezolizumab (non-small cell lungcancer) ? Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Atezolizumab (nicht kleinzelliges Lungenkarzinom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 27 December 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports (...) – Commission No. A17-50 Atezolizumab (non-small cell lungcancer) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-50 Version 1.0 Atezolizumab (non-small cell lungcancer) 27 December 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Atezolizumab (non-small cell lungcancer) – Benefit assessment according to §35a Social Code Book V Commissioning agency
LungCancer Screening New 2018 ACR Appropriateness Criteria ® 1 LungCancer Screening American College of Radiology ACR Appropriateness Criteria ® LungCancer Screening Variant 1: Lungcancer screening. Patient 55 to 80 years of age and 30 or more packs per year smoking history and currently smoke or have quit within the past 15 years. Procedure Appropriateness Category Relative Radiation Level CT chest without IV contrast screening Usually Appropriate ??? CT chest with IV contrast Usually (...) Not Appropriate ??? CT chest without and with IV contrast Usually Not Appropriate ??? FDG-PET/CT skull base to mid-thigh Usually Not Appropriate ???? MRI chest without and with IV contrast Usually Not Appropriate O MRI chest without IV contrast Usually Not Appropriate O Radiography chest Usually Not Appropriate ? Variant 2: Lungcancer screening. Patient 50 years of age or older and 20 or more packs per year history of smoking and one additional risk factor (ie, radon exposure or occupational exposure
Anti-tumour effect of low molecular weight heparin in localised lungcancer: a phase III clinical trial The anti-tumour and anti-metastatic properties of heparins have not been tested in patients with early stage cancer. Whether adjuvant low molecular weight heparin (LMWH) tinzaparin impacts the survival of patients with resected non-small cell lungcancer (NSCLC) was investigated.Patients with completely resected stage I, II or IIIA NSCLC were randomly allocated to receive subcutaneous
CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell LungCancer Purpose We report CNS efficacy of osimertinib versus standard epidermal growth factor receptor ( EGFR) tyrosine kinase inhibitors (TKIs) in patients with untreated EGFR-mutated advanced non-small-cell lungcancer from the phase III FLAURA study. Patients and Methods Patients (N = 556) were randomly assigned (...) , 1.2 to 5.2; P = .011) treated with osimertinib and standard EGFR-TKIs, respectively. Probability of experiencing a CNS progression event was consistently lower with osimertinib versus standard EGFR-TKIs. Conclusion Osimertinib has CNS efficacy in patients with untreated EGFR-mutated non-small-cell lungcancer. These results suggest a reduced risk of CNS progression with osimertinib versus standard EGFR-TKIs.
Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lungcancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study Antibodies targeting the immune checkpoint molecules PD-1 or PD-L1 have demonstrated clinical efficacy in patients with metastatic non-small-cell lungcancer (NSCLC). In this trial we investigated the efficacy and safety of avelumab, an anti-PD-L1 antibody, in patients with NSCLC who had already received platinum-based therapy.JAVELIN Lung (...) 200 was a multicentre, open-label, randomised, phase 3 trial at 173 hospitals and cancer treatment centres in 31 countries. Eligible patients were aged 18 years or older and had stage IIIB or IV or recurrent NSCLC and disease progression after treatment with a platinum-containing doublet, an Eastern Cooperative Oncology Group performance status score of 0 or 1, an estimated life expectancy of more than 12 weeks, and adequate haematological, renal, and hepatic function. Participants were randomly
Smoking and LungCancer Mortality in the United States From 2015 to 2065: A Comparative Modeling Approach. Tobacco control efforts implemented in the United States since the 1960s have led to considerable reductions in smoking and smoking-related diseases, including lung cancer.To project reductions in tobacco use and lungcancer mortality from 2015 to 2065 due to existing tobacco control efforts.Comparative modeling approach using 4 simulation models of the natural history of lungcancer (...) that explicitly relate temporal smoking patterns to lungcancer rates.U.S. population, 1964 to 2065.Adults aged 30 to 84 years.Models were developed using U.S. data on smoking (1964 to 2015) and lungcancer mortality (1969 to 2010). Each model projected lungcancer mortality by smoking status under the assumption that current decreases in smoking would continue into the future (status quo trends). Sensitivity analyses examined optimistic and pessimistic scenarios.Under the assumption of continued decreases
Tobacco smoking and cessation and PD-L1 inhibitors in non-small cell lungcancer (NSCLC): a review of the literature Programmed death ligand 1 (PD-L1) targeting immunotherapies, as pembrolizumab and nivolumab, have significantly improved outcome in patients with non-small cell lungcancer (NSCLC). Tobacco smoking is the number one risk factor for lungcancer and is linked to 80%-90% of these cancers. Smoking during cancer therapy may influence on radiotherapy and chemotherapy outcome. We aimed (...) to review the knowledge in immunotherapy.A systematic review was done. We searched for documents and articles published in English language and registered in Cochrane Library, National Health Service (NHS) Centre for Reviews and Dissemination (CRD), Embase or Medline. The search terms were (A) (Lungcancer or NSCLC) with (pembrolizumab or nivolumab) with PD-L1 with (tobacco or smoking) and (B) Lung Neoplasms and Immunotherapy and (smoking cessation or patient compliance). 68 papers were detected and two
ASTRO's guideline on Palliative Radiation Therapy for Non-Small Cell LungCancer Special Article Palliative thoracic radiation therapy for non- small cell lungcancer: 2018 Update of an American Society for Radiation Oncology (ASTRO) Evidence-Based Guideline Benjamin Moeller MD, PhD a, ? , Ehsan H. Balagamwala MD b , Aileen Chen MD c , Kimberly M. Creach MD d , Giuseppe Giaccone MD, PhD e , Matthew Koshy MD f , Sandra Zaky MD, MS g , George Rodrigues MD, PhD, FASTRO h a Department of Radiation (...) Oncology Center, Turlock, California h Department of Radiation Oncology, London Health Sciences Centre, London, Ontario, Canada Received 6 February 2018; accepted 19 February 2018 Abstract Purpose: To revise the recommendation on the use of concurrent chemotherapy (CC) with palliative thoracic external beam radiation therapy (EBRT) made in the original 2011 American Society for Radiation Oncology guideline on palliative thoracic radiation for lungcancer. Methods